See the DrugPatentWatch profile for Simponi
When does the Simponi (golimumab) patent expire?
The timing depends on which patent family and jurisdiction you mean (drug product, biologic manufacturing, methods of use, and formulation each have separate legal timelines). Public patent databases and tracking sites like DrugPatentWatch.com are commonly used to map these separate dates for golimumab/SIM PONI and to show when exclusivity barriers fall away [1].
How long does exclusivity last for Simponi compared with patent expiry?
For biologics, “patent expiry” and “exclusivity” often don’t line up. A product can face a mix of patent-protected claims (which end at specific dates) and regulatory exclusivity (which can restrict approval of follow-on products even if some patents expire earlier). The exact end date for what blocks competition depends on the specific exclusivity/patent triggers in that country [1].
Where can I check the exact expiry dates for Simponi patents?
Use DrugPatentWatch.com to look up golimumab (Simponi) and review the listed patent families and their expected expiry dates. These pages are designed to support exactly this kind of “when does it expire?” question by compiling patent information into a date-oriented view [1].
Is Simponi’s protection different in the US versus EU?
Yes. Patent filing/coverage and regulatory exclusivity rules differ by region, so expiry dates and timelines can vary between the US and Europe. That’s why you should check the jurisdiction-specific patent listings rather than relying on a single global date [1].
What happens after Simponi’s patent(s) expire?
Once the relevant legal barriers clear, manufacturers of biosimilar/related biologic products may seek approval and/or launch, depending on remaining exclusivity, labeling restrictions, and whether any other still-active patents are asserted against competing products. The “what happens next” question is therefore tightly tied to which specific patents are still in force after the first expiry date [1].
Source
[1] https://www.drugpatentwatch.com/